CVD Remains Leading Killer, but COVID s Impact Still Unclear medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
February is
Heart Awareness Month. That s good. We need to be as aware as possible of these ticking keepers of life pumping inside of our bodies.
According to the
American Heart Association s 2019 Heart Disease and Stroke Statistics report, heart-related disease remains the top cause of death for Americans. Want a grim statistic? Linda R. Bernstein, Pharm D. of
Vita Media Corporation recently confirmed the data showing that someone in the United States has a
heart attack every 40 seconds. That s a sobering thought.
Let s review some of the most important things you can do and changes you can make to keep your heart as healthy as possible.
E-Mail
DALLAS, Jan. 27, 2021 Heart disease remains the leading cause of death worldwide, according to the American Heart Association s Heart Disease and Stroke Statistics 2021 Update, published today in the Association s flagship journal
Circulation, and experts warn that the broad influence of the COVID-19 pandemic will likely continue to extend that ranking for years to come.
Globally, nearly 18.6 million people died of cardiovascular disease in 2019, the latest year for which worldwide statistics are calculated. That reflects a 17.1% increase over the past decade. There were more than 523.2 million cases of cardiovascular disease in 2019, an increase of 26.6% compared with 2010.
Experts predict the global burden of cardiovascular disease will grow exponentially over the next few years as the long-term effects of the current COVID-19 pandemic evolve.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Provides Preliminary 2020 Results and 2021 Outlook
Amarin Corporation plcJanuary 7, 2021 GMT
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019
Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA® (icosapent ethyl) Expected in Late January or February 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2020 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 39th Annual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present on Tuesday, January 12, 2020, at 2:00 pm Eastern time.
At 15:03 on an otherwise-normal afternoon in 2014, an 85-year-old male developed a sudden onset of right-sided weakness. Upon witnessing his symptoms, a family member called emergency medical services at 15:08. At 15:13 EMS arrived.
The crew’s initial exam demonstrated an alert and oriented 100-kg geriatric male with marked weakness of his right arm and leg. His past medical history included coronary artery disease, chronic obstructive pulmonary disease, deep vein thrombosis status post-IVC filter, hypertension, and chronic atrial fibrillation. As scene time progressed, the patient became progressively aphasic and altered, with a final Cincinnati Stroke Scale score of 2 for arm drift and slurred speech.